But doctors and health experts are divided on whether it warranted an accelerated FDA approval. While some of them have praised the agency’s decision, describing the drug as groundbreaking, others are skeptical about whether it provides a substantial benefit.
In the U.S., over 6 million people are living with Alzheimer’s, an incurable and fatal disease that affects the brain and causes loss of cognitive function over time. While there are available medications that can treat Alzheimer’s symptoms, there have been no treatments that address the underlying cause of the disease. This is why some doctors have welcomed the accelerated approval of lecanemab. The FDA is likely to consider a full approval later this year.